On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin

These days, with its revenue booming and a market cap swelling to twice the size of any other pharma company in the U.S., Eli Lilly is doing everything in a big way.

One piece of the puzzle that didn’t seem to fit for the Indianapolis drugmaker came in April when it spent a mere $100 million to purchase a manufacturing facility in Kenosha, Wisconsin, from Nexus Pharmaceuticals. Now, eight months later, Lilly has made sense of its move in the Badger state, upping its ante there with another prodigious investment.